Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Authors:
Camille F. Ng Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, and

Search for other papers by Camille F. Ng in
Current site
Google Scholar
PubMed Close
 BS
,
John Glaspy Jonsson Comprehensive Cancer Center, University of California, Los Angeles School of Medicine, Los Angeles, California.

Search for other papers by John Glaspy in
Current site
Google Scholar
PubMed Close
 MD
,
Veronica R. Placencio-Hickok Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, and

Search for other papers by Veronica R. Placencio-Hickok in
Current site
Google Scholar
PubMed Close
 PhD
,
Shant Thomassian Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, and

Search for other papers by Shant Thomassian in
Current site
Google Scholar
PubMed Close
 MD
,
Jun Gong Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, and

Search for other papers by Jun Gong in
Current site
Google Scholar
PubMed Close
 MD
,
Arsen Osipov Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, and

Search for other papers by Arsen Osipov in
Current site
Google Scholar
PubMed Close
 MD
,
Andrew E. Hendifar Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, and

Search for other papers by Andrew E. Hendifar in
Current site
Google Scholar
PubMed Close
 MD
, and
Natalie Moshayedi Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, and

Search for other papers by Natalie Moshayedi in
Current site
Google Scholar
PubMed Close
 BA
Volume/Issue:
Volume 20: Issue 10
Online Publication Date:
Oct 2022
DOI:
https://doi.org/10.6004/jnccn.2022.7039
Restricted access

Despite advances in cancer therapeutics, pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a poor prognosis at time of diagnosis. Research in PDAC has suggested that adaptive signaling in the tumor microenvironment may promote tumor proliferation and survival. Several FGFR fusion genes—specifically FGFR2—are involved with the creation and progression of cancer. These mutations are found in a variety of cancer types. This report presents a unique case of a young patient with stage IV PDAC with a known FGFR2 fusion. This molecular alteration afforded a remarkable response to FGFR inhibitor therapy, erdafitinib, after the patient experienced disease progression on multiple chemotherapy regimens.

Submitted April 5, 2022; final revision received May 24, 2022; accepted for publication May 24, 2022.

Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: Natalie Moshayedi, BA, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048. Email: natalie.moshayedi@gmail.com
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.

  • 2.

    Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457–1461.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Kang X, Lin Z, Xu M, et al. Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Prolif 2019;52:e12605.

  • 4.

    Rhim AD, Stanger BZ. Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog Mol Biol Transl Sci 2010;97:41–78.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Helsten T, Elkin S, Arthur E, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 2016;22:259–267.

  • 6.

    Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. Clin Cancer Res 2015;21:2684–2694.

  • 7.

    Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol 2018;2:1–12.

  • 8.

    Lee PC, Hendifar A, Osipov A, et al. Targeting the fibroblast growth factor receptor (FGFR) in advanced cholangiocarcinoma: clinical trial progress and future considerations. Cancers (Basel) 2021;13:1706.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636–647.

  • 10.

    Poon D, Tan MH, Khor D. Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor. BMJ Case Rep 2021;14:e244271.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Hendifar AE, Blais EM, Ng C, et al. Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): clinical/molecular correlations and real-world outcomes across standard therapies [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 4641.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338–348.

  • 13.

    Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671–684.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Lowery MA, Jordan EJ, Basturk O, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res 2017;23:6094–6100.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Fusco MJ, Saeed-Vafa D, Carballido EM, et al. Identification of targetable gene fusions and structural rearrangements to foster precision medicine in KRAS wild-type pancreatic cancer. JCO Precis Oncol 2021;5:65–74.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Singhi AD, George B, Greenbowe JR, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 2019;156:2242–2253.e4.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Surveillance, Epidemiology, and End Results Program. Cancer stat facts: pancreatic cancer. Accessed January 15, 2022. Available at: https://seer.cancer.gov/statfacts/html/pancreas.html

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Moshayedi N, Escobedo AL, Thomassian S, et al. Race, sex, age, and geographic disparities in pancreatic cancer incidence [abstract]. J Clin Oncol 2022;40(Suppl):Abstract 520.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218–1249.

  • 20.

    Philip PA, Azar I, Xiu J, et al. Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res 2022;28:2704–2714.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Philip PA, Xiu J, Hall MJ, et al. Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC) [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 4629.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Singhi AD, Ali SM, Lacy J, et al. Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw 2017;15:555–562.

  • 23.

    Markham A. Erdafitinib: first global approval. Drugs 2019;79:1017–1021.

  • 24.

    Balversa [prescribing information]. Horsham, PA:Janssen Products, LP; 2019.

  • 25.

    Park JO, Feng YH, Chen YY, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alternations [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 4117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2022 by the National Comprehensive Cancer Network 2022
Page Numbers:
4
Article Category:
Research Article
Received:
05 Apr 2022
Accepted:
24 May 2022
Print Publication Date:
01 Oct 2022
Online Publication Date:
Oct 2022
Keywords:
precision oncology; FGFR2 mutations; Fusion genetics; KRAS WT PDAC

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 5136 1048 147
PDF Downloads 2455 631 62
EPUB Downloads 0 0 0